EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Enbrel 25 mg powder and solvent for solution for injection
- Sustiva 50 mg, 100 mg and 200 mg Hard Capsules
- Sandostatin LAR
- Difflam Oral Rinse
- Teoptic 1% - Teoptic 2%
- Erythroped A 500 mg Tablets
- Enalapril 5mg Tablets
- Viskaldix Tablets
- Aricept Tablets
- Difflam Cream
- Alfentanil 500 micrograms/ml solution for injection
- Revlimid
- Benadryl Plus Capsules
- Diclomax Retard
- Voltarol Tablets
- Virgan
- DIXARIT (menopausal disorders)
- Rapiscan (regadenoson)
- Neurontin Capsules and Tablets
- Aprovel Film-Coated Tablets (sanofi-aventis Bristol-Myers Squibb SNC)
- Foradil
- Nystatin-Dome Suspension 100,000 I.U./ml
- Meningitec in pre-filled syringe
- Catapres Tablets 100mcg
- Kemadrin 5 mg Tablets
- SECTRAL 400mg tablets
- Sectral 100mg and 200mg
- Eucardic 25mg Tablets
- ALDOMET Tablets 250 mg
- Parvolex 200 mg/ml Concentrate for Solution for Infusion
- Mifegyne
- Pedea 5 mg/ml solution for injection
- Eucardic 12.5mg Tablets
- Qvar 100 Easi-Breathe
- Qvar 50 Easi-Breathe
- Eucardic 6.25mg Tablets
- Qvar MDI 50 micrograms
- Sonata 5 mg hard capsules
- PRO-EPANUTIN
- Xarelto 20mg film-coated tablets
Non-Small Cell Lung Cancer (NSCLC)
Please note- The EPG Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre.
The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]).
At the start of the millennium, it was estimated that there were 10 million new cancer cases worldwide per annum
The causes of lung cancer are thought to be almost exclusively environmental, although susceptibility is modulated by protective elements such as genetic factors and diet.1
The staging of lung cancer is based on the size and invasiveness of the primary tumour (T), absence, presence and degree of regional lymph node (N) involvement, and the metastatic spread to distant organs and lymph nodes (M), or TNM system.
In around 5% of cases, usually of early-stage disease, initial presentation is a chance finding during routine examination for other conditions and no symptoms are evident.
Following presentation and diagnosis of NSCLC, thorough examination allows determination of the disease stage to provide a prognosis at the individual patient level.
The treatment strategies for NSCLC are principally dictated by clinical stage with modulation according to patient preferences and characteristics such as age and PS
The four primary treatment modalities used in the management of patients with NSCLC are:2
- Surgery
- Radiation therapy
- Combination chemotherapy
- Targeted therapy
Enter the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre
What’s in the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre?
- Home
- Non-small Cell Lung Cancer
- Causes
- Risk Factors
- Histology/Pathology
- Disease Staging/Prognosis
- TNM Systems
- Factors that affect prognosis
- Signs and Symptoms
- Diagnosis
- Early Stage disease (stage I, II, IIIA)
- Treatment Strategies
- Advanced disease (stage IV)
- Quality of Life in advanced NSCLC
- Future Strategies
- Treatment Therapies
- Chemotherapy
- First-line Therapy
- Second-line Therapy
- Unmet clinical need in advanced NSCLC
- Targeted therapies - Overview of cytotoxic drugs
- Recent developments in Cancer Cell Biology
- Current therapy - Erlotinib
- Resources
- Downloads - Physicians Materials
- Patient
- Downloads - Patient support
References:
1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S–49S.
2. Putnam JB, Fossella FV, Komaki R, eds. Implementation of multidisciplinary care in the treatment of patients with lung cancer. In: Fossella FV, Komaki R, Putnam JB, eds. Lung Cancer. New York, NY: Springer-Verlag; 2003:1-24
